Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Chronic Lymphoproliferative Disease

NCT00124189 is registered in ClinicalTrials.gov with Geron Corporation as lead sponsor.

NCT NCT00124189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00124189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Chronic Lymphoproliferative Disease
Lead sponsor
Geron Corporation
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2005
Completion date
March 31, 2013
Enrollment
48 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphoproliferative diseases